Science Explorer Back to mapMap
Discussion
Company · Aptos · United States

Orbus Therapeutics (United States)

Research works
6
▲ 48% vs 2018-21
Citations
7
1.2 per fractional work
Top-10% rate
14.7%
all institutions 10.0%
Open access
62%
world 40%
International
13%
world 18%
Orbus Therapeutics (United States)

Not ranked overall: Orbus Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Orbus Therapeutics (United States) work in?

In all years, 70% of research at Orbus Therapeutics (United States) is in Life Sciences, 29% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (70%), Medicine (19%), Veterinary (10%). It does 1.8× the world's share of Life Sciences.

Life Sciences: 4 fractional works · 70.0% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 69.8% of its workMolecular Biology: 2 fractional works · 36.3% of its workBiotechnology: 1 fractional works · 12.0% of its workBiochemistry: 1 fractional works · 11.8% of its workCancer Research: 1 fractional works · 9.0% of its workCell Biology: 0 fractional works · 0.9% of its workImmunology and Microbiology: 0 fractional works · 0.2% of its workImmunology: 0 fractional works · 0.2% of its workHealth Sciences: 2 fractional works · 28.9% of its workMedicine: 1 fractional works · 19.0% of its workDermatology: 0 fractional works · 5.8% of its workGenetics: 0 fractional works · 3.5% of its workRehabilitation: 0 fractional works · 3.0% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 1.4% of its workEpidemiology: 0 fractional works · 1.4% of its workPathology and Forensic Medicine: 0 fractional works · 1.4% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.2% of its workOncology: 0 fractional works · 1.1% of its workSmaller subfields together: 0 fractional works · 0.2% of its workVeterinary: 1 fractional works · 9.9% of its workSmall Animals: 1 fractional works · 9.9% of its workPhysical Sciences: 0 fractional works · 1.1% of its workEngineering: 0 fractional works · 1.1% of its workBiomedical Engineering: 0 fractional works · 1.1% of its workALL ITS WORKOrbusTherapeutics…6fractional works, all years
Life Sciences70%Physical Sciences1%Health Sciences29%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 5 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology469.8%
    2. Immunology and Microbiology00.2%
    1. Medicine119.0%
    2. Veterinary19.9%
    1. Engineering01.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Orbus Therapeutics (United States)?

The most cited paper from Orbus Therapeutics (United States) is "Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update" (Jaishri O'Neill Blakeley et al., 2025), with 15 citations. Next come "Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma" (10) and "Integrating Human Intestinal Organoids into FDA's New Approach Methodologies for Drug Discovery" (4).

Most cited papers
#PaperReleasedCitations
1 Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update Jaishri O'Neill Blakeley et al. · Journal of Clinical Oncology Open access 29 Apr 2025 15
2 Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma Joe Sammy Mendez et al. · Neuro-Oncology Advances Open access 2024 10
3 Integrating Human Intestinal Organoids into FDA's New Approach Methodologies for Drug Discovery Debarun Patra, Ibrahim M. Sayed, Souhrid Mukherjee et al. · Advanced Science Open access 2 Mar 2026 4
4 A scoping review of the treatment of hypertrophic scars and keloids Benjamin Michael Davies, Alison R. Carter, David A. Brindley · Dermatological Reviews Open access 21 Feb 2022 4
5 Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells Noymi Yam, Jason Levin, Zheng‐Zheng Bao et al. · Oncotarget Open access 3 Nov 2020 3
All 9 most cited papers, with filters and sorting

Which research topics does Orbus Therapeutics (United States) publish most on?

By volume in 2022-now: Dermatologic Treatments and Research, Facial Rejuvenation and Surgery Techniques, Wound Healing and Treatments and 3D Printing in Biomedical Research.

  1. 1 Dermatologic Treatments and Research Dermatology 0 works
  2. 2 Facial Rejuvenation and Surgery Techniques Dermatology 0 works
  3. 3 Wound Healing and Treatments Rehabilitation 0 works
  4. 4 3D Printing in Biomedical Research Biomedical Engineering 0 works
  5. 5 Cardiac Ischemia and Reperfusion Pathology and Forensic Medicine 0 works
  6. 6 Cardiac Fibrosis and Remodeling Cardiology and Cardiovascular Medicine 0 works
  7. 7 Autophagy in Disease and Therapy Epidemiology 0 works
  8. 8 Cancer Cells and Metastasis Oncology 0 works
  9. 9 Animal testing and alternatives Small Animals 0 works
  10. 10 Protein Kinase Regulation and GTPase Signaling Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available62.1%not open37.9%

World: 40% of research is openly available.

with international co-authors13.1%domestic only86.9%

World: 18% is written across borders.

How has Orbus Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 48% higher than in 2018-2021.

still counting20202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Aptos

All research institutions in Aptos

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Orbus Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.